...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology international >A randomized,, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil pies bicyclol
【24h】

A randomized,, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil pies bicyclol

机译：阿德福韦酯或阿德福韦酯双环糊精治疗的乙型肝炎e抗原阳性慢性乙型肝炎患者的随机，多中心对照研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective To evaluate the efficacy and safety profiles of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) treated with adefovir dipivoxil (ADV) or ADV plus bicyclol, and to optimize the treatment strategy for CHB patients.Patients and methods A total of 250 patients with HBeAg-positive CHB were randomized to ADV plus bicyclol combination group and ADV monotherapy group. The patients in the ADV plus bicyclol combination therapy group (n = 125) received ADV 10 mg orally q.d. and bicyclol 25 mg orally t.i.d. for 48 weeks, and those in the ADV monotherapy group (n = 125) were administered ADV 10 mg orally q.d. alone for 48 weeks. The serum aminotransferases (ALT/AST), HBV DNA, HBeAg/HBeAb, and liver biopsy were conducted before and after therapy.Results The serum aminotransferase levels were decreased significantly in both groups. The serum aminotransferase level in ADV plus bicyclol combination therapy group decreased greater than that in ADV monotherapy group (P < 0.01). The virological response rate in ADV plus bicyclol combination therapy group was not significantly different from that in ADV monotherapy group (P > 0.05). After treatment for 48 weeks, the Knodell necroinflammatory score of the two groups were all alleviated significantly, and the Knodell score in the combination group was significantly lower than that in the ADV monotherapy group (P < 0.05). There were no remarkable adverse events probably related to the drag in this study. Conclusion Adefovir dipivoxil plus bicyclol combination therapy is a safe and superior treatment regimen for patients with HBeAg-positive CHB when compared with ADV monotherapy.
机译：目的评估阿德福韦酯（ADV）或ADV加双环醇治疗乙型肝炎e抗原（HBeAg）阳性的慢性乙型肝炎（CHB）的疗效和安全性，并优化CHB患者的治疗策略。方法将250例HBeAg阳性CHB患者随机分为ADV加双环联合治疗组和ADV单药治疗组。 ADV加双环合剂治疗组（n = 125）的患者每天口服10 mg ADV。和双环醇25毫克口服t.i.d.持续48周，ADV单药治疗组（n = 125）每日一次口服10 mg ADV。一个人呆了48周。治疗前后分别进行血清氨基转移酶（ALT / AST），HBV DNA，HBeAg / HBeAb和肝活检。结果两组血清氨基转移酶水平均明显降低。 ADV加双环合剂治疗组的血清转氨酶水平下降幅度大于ADV单药治疗组（P <0.01）。 ADV加双环联合治疗组的病毒学应答率与ADV单药治疗组的病毒学应答率无显着差异（P> 0.05）。治疗48周后，两组的Knodell坏死炎症评分均明显减轻，联合组的Knodell得分明显低于ADV单药治疗组（P <0.05）。在这项研究中，没有明显的不良事件可能与药物的拖累有关。结论与ADV单药治疗相比，阿德福韦酯+双环醇联合治疗对HBeAg阳性CHB患者是一种安全，优越的治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号